Clinical Study

A Randomized Phase II Pilot Study Prospectively Evaluating Treatment For Patients Based On Ercc1 (Excision Repair Cross-Complementing 1) For Advanced/

Posted Date: May 15, 2019

  • Investigator: John Morris
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to find out what effects (good and bad) a targeted therapy approach has on esophageal, gastric, or gastroesophageal junction cancer. About 225 people will take part in this study with approximately 6 people participating locally.

Criteria:

Eligible Patients Must Have Advanced Esophageal, Gastric, Or Gastroesophageal Junction Cancer

Keywords:

Esophageal, Gastric, Gastrointestinal Can, Gej, S1201

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.